A Prospective Exploratory Single-Center Diagnostic Imaging Study Evaluating the Diagnostic Performance of 18F-labeled Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Diffuse Gastric Cancer: Protocol for the FAPI-DGC Study
JMIR Research Protocols · 2026-11-20 · 15 · e105341
DOI: 10.2196/105341 ↗At a glance
Studienprotokoll in JMIR Research Protocols, published online on 2026-11-20. Written by Yoshimasa Akashi and 9 co-authors. 30 references.
Abstract (original language)
Background
Accurate preoperative staging remains challenging in diffuse gastric cancer (DGC), which is characterized by poorly differentiated or signet ring cell histology, diffuse submucosal infiltration, stromal fibrosis, and a high propensity for peritoneal dissemination. Contrast-enhanced computed tomography (ceCT) may underestimate tumor depth, nodal involvement, and small-volume metastatic disease, whereas the diagnostic value of fluorodeoxyglucose (FDG)–positron emission tomography (PET) is limited in diffuse histological subtypes. Fibroblast activation protein inhibitor (FAPI)–PET targets cancer-associated fibroblasts and may provide additional biological information beyond conventional imaging.
Objective
The FAPI-DGC (Fibroblast Activation Protein Inhibitor Diffuse Gastric Cancer) study aims to evaluate the diagnostic performance, potential clinical value, and safety of adding fluorine-18 (18F)–labeled FAPI positron emission tomography/computed tomography (PET/CT) to conventional preoperative staging in patients with DGC.
Methods
This prospective exploratory diagnostic imaging study will enroll 20 adults with biopsy-confirmed poorly differentiated adenocarcinoma or signet ring cell carcinoma who are scheduled to undergo curative gastrectomy or staging laparoscopy. All participants will undergo 18F-labeled FAPI-74 PET/CT in addition to standard preoperative investigations, including ceCT. Preoperative tumor, node, and metastasis (TNM) staging based on conventional preoperative staging, including ceCT, and on staging incorporating FAPI-PET findings will be compared with postoperative pathological staging as the reference standard. The primary outcome is the exploratory assessment of preoperative staging accuracy. Secondary outcomes include detection rates of primary and metastatic lesions; correlations between FAPI uptake and histopathological features, including fibrosis and fibroblast activation protein expression; associations with serum tumor markers; and safety outcomes. Accuracy estimates with corresponding 95% CIs will be reported, and paired comparisons will be performed using appropriate exact statistical methods, where applicable.
Results
Research funding was approved in August 2025. Participant recruitment commenced on November 19, 2025. As of July 30, 2026, a total of 6 participants have been enrolled. Recruitment is planned to continue until March 2027, with study follow-up scheduled to be completed by June 2029. Data analysis will commence after completion of participant recruitment. The primary study results are expected to be published by the end of 2029.
Conclusions
This protocol describes a prospective exploratory diagnostic imaging study evaluating 18F-FAPI-PET/CT for preoperative staging of DGC. Publication of this protocol will enhance transparency, establish an a priori record of the study methodology, and facilitate interpretation of subsequent study findings while informing the design of future confirmatory diagnostic imaging studies. Trial Registration Japan Registry of Clinical Trials jRCTs031250386; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031250386 International Registered Report Identifier (IRRID) DERR1-10.2196/105341
Cite
APA
Akashi, Y., Ogawa, K., Owada, Y., Hatano, K., Hara, T., Shimizu, M., Miyazaki, Y., Furuya, K., Nakajima, T., & Oda, T. (2026). A Prospective Exploratory Single-Center Diagnostic Imaging Study Evaluating the Diagnostic Performance of 18F-labeled Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Diffuse Gastric Cancer: Protocol for the FAPI-DGC Study. JMIR Research Protocols, 15, e105341. https://doi.org/10.2196/105341
Vancouver
Akashi Y, Ogawa K, Owada Y, Hatano K, Hara T, Shimizu M, et al. A Prospective Exploratory Single-Center Diagnostic Imaging Study Evaluating the Diagnostic Performance of 18F-labeled Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Diffuse Gastric Cancer: Protocol for the FAPI-DGC Study. JMIR Research Protocols. 2026;15:e105341. doi:10.2196/105341
BibTeX
@article{Akashi2026,
author = {Akashi, Yoshimasa and Ogawa, Koichi and Owada, Yohei and Hatano, Kentaro and Hara, Tadashi and Shimizu, Masaru and Miyazaki, Yoshihiro and Furuya, Kinji and Nakajima, Takahito and Oda, Tatsuya},
title = {A Prospective Exploratory Single-Center Diagnostic Imaging Study Evaluating the Diagnostic Performance of 18F-labeled Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Diffuse Gastric Cancer: Protocol for the FAPI-DGC Study},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e105341},
doi = {10.2196/105341}
}
EUVIMED